Investigator
Jon Jacobs
BATTELLE PACIFIC NORTHWEST LABORATORIES · funded by NIGMS, NIDA
- Companies
- 3
- Grants
- 4
- Non-dilutive funding
- $2.0M
- First award
- Sep 1, 2019
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Jun 15, 2023.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- BATTELLE PACIFIC NORTHWEST LABORATORIESMomentum in another area
NeuroGrant-only
- BATTELLE PACIFIC NORTHWEST LABORATORIESMomentum in another area
ImmunologyGrant-only
- BATTELLE PACIFIC NORTHWEST LABORATORIESMomentum in another area
ImmunologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R01
A Novel high resolution MS platform for high-throughput screening of G protein-coupled receptors
$481kJun 15, 2023NIGMSBATTELLE PACIFIC NORTHWEST LABORATORIESNIH RePORTER · 11055999 (opens the source filing in a new tab)
- R01
A Novel high resolution MS platform for high-throughput screening of G protein-coupled receptors
$465kJun 15, 2023NIGMSBATTELLE PACIFIC NORTHWEST LABORATORIESNIH RePORTER · 11324211 (opens the source filing in a new tab)
- U54
PSP Omics Center of Acute to Chronic Pain Signatures
$527kSep 1, 2019NIDABATTELLE PACIFIC NORTHWEST LABORATORIESNIH RePORTER · 11160479 (opens the source filing in a new tab)
- U54
PSP-Administrative Core
$527kSep 1, 2019NIDABATTELLE PACIFIC NORTHWEST LABORATORIESNIH RePORTER · 11160480 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources